CLAIMS

1. A pharmaceutical composition having a single dosage form comprising a compartment comprising olmesartan medoxomil; and a compartment comprising rosuvastatin or its salt,

wherein said compartments are formulated in a separate form,

wherein the compartment comprising olmesartan medoxomil comprises one or more disintegrant selected from the group consisting of carboxymethylcellulose calcium, croscarmellose sodium, crospovidone, sodium starch glycolate, and pregelatinized starch, and

wherein the compartment comprising rosuvastatin or its salt comprises one or more disintegrant selected from the group consisting of crospovidone, low substituted hydroxypropyl cellulose, croscarmellose sodium, and carboxymethylcellulose calcium.

2. The pharmaceutical composition according to claim 1, having a double-layered tablet form, a tablet form consisting essentially of an inner core and an outer layer, or a pellet-containing capsule form.

3. The pharmaceutical composition according to claim 1, having a double-layered tablet form consisting essentially of a layer comprising rosuvastatin or its salt and a layer comprising olmesartan medoxomil.

4. The pharmaceutical composition according to claim 1, having a tablet form consisting essentially of an inner core comprising rosuvastatin or its salt and an outer layer comprising olmesartan medoxomil.

5. The pharmaceutical composition according to claim 1, having a capsule form filled with pellets comprising rosuvastatin or its salt and pellets comprising olmesartan medoxomil.

6. The pharmaceutical composition according to claim 1, wherein the disintegrant in the compartment comprising rosuvastatin or its salt is present in an amount ranging from 2 to 20 % by weight, based on the total weight of the compartment comprising rosuvastatin or its salt.

7. The pharmaceutical composition according to claim 1, wherein the compartment comprising olmesartan medoxomil comprises 5 or more % by weight of carboxymethylcellulose calcium, 15 or more % by weight of croscarmellose sodium, 10 or more % by weight of crospovidone, 5 or more % by weight of sodium starch glycolate, or 5 or more % by weight of pregelatinized starch, based on the total weight of the compartment comprising olmesartan medoxomil.

8. The pharmaceutical composition according to claim 1, wherein the compartment comprising olmesartan medoxomil comprises 5 to 60 % by weight of carboxymethylcellulose calcium, 15 to 30 % by weight of croscarmellose sodium, 10 to 40 % by weight of crospovidone, 5 to 40 % by weight of sodium starch glycolate, or 5 to 60 % by weight of pregelatinized starch, based on the total weight of the compartment comprising olmesartan medoxomil.